Our extensive portfolio includes plasma, serum, whole blood, urine, saliva, cerebrospinal fluid (CSF), fresh and frozen tissues, FFPE samples, PBMCs, exosomes, and cellular derivatives, all paired with comprehensive clinical, demographic, and outcome metadata.
Our biospecimens support biomarker research across a broad spectrum of therapeutic areas including oncology, neurology, cardiovascular disease, autoimmune disorders, metabolic syndromes such as diabetes and obesity, neurodegenerative diseases like Alzheimer’s and Parkinson’s, infectious diseases, and rare disorders. Each sample is collected using standardized SOPs to maintain molecular integrity, minimize pre-analytical variability, and ensure reproducibility across high-throughput platforms.
We enable researchers to uncover diagnostic, prognostic, predictive, and pharmacodynamic biomarkers that drive precision medicine and targeted therapies. Our scalable collection programs support longitudinal studies, multi-site clinical trials, and population-based research — accelerating timelines while maintaining regulatory compliance.
From hypothesis-driven discovery to real-world clinical validation, we deliver customizable biospecimen solutions that increase confidence in biomarker performance and translational success.
Proteomic, metabolomic, lipidomic, and multi-omics profiling
Genomic, epigenomic, and transcriptomic biomarker discovery
Liquid biopsy development and circulating biomarker analysis
Longitudinal biomarker tracking and disease progression studies
Companion diagnostic and patient stratification research
Clinical sensitivity, specificity, and reproducibility validation
Therapeutic response and resistance monitoring
